兆科眼科-B（06622）今日盘中大跌6.51%，引发市场关注。该公司于昨日晚间发布了2024年度财务业绩报告，尽管业绩有所改善，但似乎未能满足投资者的期望。
根据公司公告，2024年兆科眼科-B实现收益6932.4万元，同比增长约2.7倍；净亏损约2.37亿元，同比收窄38.32%；每股亏损0.43元。收益增长主要来自两个方面：一是收取了一份产品许可协议的里程碑付款3350万元，二是主要眼科药品销售额增加逾五倍，达到3040万元。亏损收窄则归因于收益增加、研发开支减少以及经营效率提高。
然而，尽管财务数据显示公司业绩有所改善，但投资者似乎对这一结果并不满意。盘中大跌可能反映出市场对公司仍处于亏损状态的担忧，以及对收益增长很大程度上依赖一次性付款的忧虑。此外，投资者可能期待看到更加显著的业绩改善。这种市场反应表明，投资者对兆科眼科-B的未来盈利能力和可持续增长前景仍持谨慎态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.